Related Experiment Video
Updated: Jul 17, 2026

Feeding of Ticks on Animals for Transmission and Xenodiagnosis in Lyme Disease Research
Published on: August 31, 2013
Propensity to excessive proinflammatory response in chronic Lyme borreliosis
Kai E Kisand1, Tiina Prükk, Kalle V Kisand
1Department of Immunology, Institute of General and Molecular Pathology, Centre of Molecular and Clinical Medicine, Tartu, Estonia. Kai.Kisand@ut.ee
Abstract:
The clinical course of Lyme borreliosis is extremely variable. However, all the clinical manifestations, acute or chronic, are characterized by strong inflammation. Borrelia burgdorferi can induce the production of several proinflammatory and anti-inflammatory cytokines. The aim of our study was to find out whether the balance between inflammatory and regulatory mechanisms is important in determining the course of Lyme borreliosis. 13 patients with early Lyme borreliosis, 8 patients with chronic Lyme disease with neurological or joint manifestations, and 15 age- and sex-matched healthy controls were studied. Chronic forms of Lyme borreliosis were characterized by stronger TNF-alpha response by monocytes to lipopolysaccharide as well as to borrelia antigen compared to early Lyme borreliosis and the healthy state. The percentage of IL-10-secreting monocytes in response to borrelia lysate was lower in the Lyme borreliosis patients than in healthy controls. The percentage of CD4(+) CTLA-4(+) regulatory T cells showed the highest values in early Lyme borreliosis. We conclude that chronic forms of Lyme borreliosis can evolve due to an aberrant innate proinflammatory response.
Related Concept Videos
Chronic Inflammation: Introduction
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Acute Inflammation III: Local and Systemic Effects
Acute Inflammation I: Inflammatory Response
Inflammatory Bowel Disease II: Ulcerative Colitis

